stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) EPS (diluted)
Alnylam Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was $2.33, compared with −$2.18 in fiscal 2024. Over the twelve months to 30 September 2026 it was $19.26. Over the past ten years it has ranged from −$9.30 (fiscal 2022) to $2.33 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. Alnylam Pharmaceuticals, Inc. ranks 8th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.33 | — |
| FY2024 | −$2.18 | — |
| FY2023 | −$3.52 | — |
| FY2022 | −$9.30 | — |
| FY2021 | −$7.20 | — |
| FY2020 | −$7.46 | — |
| FY2019 | −$8.11 | — |
| FY2018 | −$7.57 | — |
| FY2017 | −$5.42 | — |
| FY2016 | −$4.79 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $15.72 | 1,199.17% |
| Jun 2026 | $1.21 | (19.87%) |
| Mar 2026 | $1.51 | 84.15% |
| Dec 2025 | $0.82 | (55.43%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | $19.26 |
| ASND Ascendis Pharma A/S compare | $12.89 |
| EXEL Exelixis, Inc. compare | $3.34 |
| JAZZ Jazz Pharmaceuticals PLC compare | $2.95 |
| INCY Incyte Corporation compare | $1.88 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| INSM Insmed, Inc. compare | −$2.82 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ALNY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement